3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
14
Leukemia, Erythroblastic, Acute
5
Leukemia
5
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Congenital Abnormalities
4
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Neoplasm, Residual
1
Myelodysplastic Syndromes
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
osimertinib
1
obinutuzumab
1
midostaurin
1
flumatinib
1
fludarabine
1
Radiotherapy
1
Oxaliplatin
1
Mitoxantrone
1
Mercaptopurine
1
Leucovorin
1
Irinotecan
1
Gemtuzumab
1
Folfox protocol
1
Fluorouracil
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm, Residual
×
Gemtuzumab
×
Clear all
NCT02724163
2021-10-08
Myechild01
University of Birmingham
Phase 3
Recruiting
700 enrolled